Skip to content

Organoids for Bile Leaks

A Prospective Study Using Patient-Derived Extrahepatic Cholangiocyte Organoids for Refractory Bile Leaks

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07214649
Acronym
ASCORB
Enrollment
25
Registered
2025-10-09
Start date
2026-01-31
Completion date
2030-12-31
Last updated
2025-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Anastomosis Complication

Keywords

biliary leaks, cholangiocyte organoids

Brief summary

Background: Bile leakage remains a major complication after hepatobiliary surgery and liver transplantation. While most cases are managed through standard radiologic or endoscopic interventions, a subset of patients fails to respond and may face recurrent interventions or even retransplantation. Recent advances in regenerative medicine, particularly the development of extrahepatic cholangiocyte organoids (ECOs), offer a promising alternative. Objective: This prospective, 5-year study aims to evaluate the feasibility, safety, and efficacy of autologous ECO-based cell therapy to reconstruct bile ducts in patients with persistent bile leakage unresponsive to standard care. Methods: Patients undergoing hepatobiliary or liver transplant surgery will have a biopsy of extrahepatic bile duct tissue collected perioperatively. The tissue will be processed and stored in a dedicated biobank. Upon development of a refractory bile leak, ECOs will be generated from the stored tissue and delivered to the site of injury through radiological or endoscopic routes, as decided by a multidisciplinary team. Success will be evaluated by resolution of leakage (radiologically or endoscopically) and absence of further intervention. Significance: The use of patient-specific ECOs holds transformative potential. Organoids can be derived and expanded in vitro while maintaining cholangiocyte identity and function. Preclinical studies in murine and human models show successful engraftment and functional integration into biliary epithelium. Expected Outcomes: This project aims to pioneer a novel, minimally invasive, personalized regenerative therapy for otherwise intractable biliary complications.

Interventions

Engrafment of the Cholangiocyte Organoids in the common bile duct with leakage

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Age over 18 years old * Undergone HPB surgical procedure with hepatic duct reconstruction * Presence of anastomotic bile leakage untreatable with radiological or endoscopic approach * Presence of bile duct specimen

Exclusion criteria

* Age under 18 years old * Undergone HPB surgical procedure without hepatic duct reconstruction * Absence of anastomotic bile leakage untreatable with radiological or endoscopic approach * Absence of bile duct specimen

Design outcomes

Primary

MeasureTime frameDescription
Treatment of the leaks1 weekAbsence of leak at radiological or endoscopic evaluation

Contacts

Primary ContactMarco M Pascale, MD
pascale.marco.maria@gmail.com0039 3888264297

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026